ADVERTISEMENT
  • The Membership Club
  • PT Hausa
  • About Us
  • Advert Rates
  • Careers
  • Contact Us
Friday, April 23, 2021
Premium Times Nigeria
  • Home
  • Gender
  • News
    • Headline Stories
    • Top News
    • More News
    • Foreign
  • Investigations
  • Business
    • News Reports
    • Financial Inclusion
    • Analysis and Data
    • Business Specials
    • Opinion
    • Oil/Gas Reports
      • FAAC Reports
      • Revenue
  • Opinion
  • Health
    • COVID-19
    • News Reports
    • Investigations
    • Data and Infographics
    • Health Specials
    • Features
    • Events
    • Primary Health Tracker
  • Agriculture
    • News Report
    • Research & Innovation
    • Data & Infographics
    • Special Reports/Features
    • Investigations
    • Interviews
    • Markets
  • Arts/Life
    • Arts/Books
    • Kannywood
    • Lifestyle
    • Music
    • Nollywood
    • Travel
  • Sports
    • Football
    • More Sports News
    • Sports Features
  • Projects
    • #EndSARS Dashboard
    • Parliament Watch
    • Panama Papers
    • Paradise Papers
    • AGAHRIN
  • Home
  • Gender
  • News
    • Headline Stories
    • Top News
    • More News
    • Foreign
  • Investigations
  • Business
    • News Reports
    • Financial Inclusion
    • Analysis and Data
    • Business Specials
    • Opinion
    • Oil/Gas Reports
      • FAAC Reports
      • Revenue
  • Opinion
  • Health
    • COVID-19
    • News Reports
    • Investigations
    • Data and Infographics
    • Health Specials
    • Features
    • Events
    • Primary Health Tracker
  • Agriculture
    • News Report
    • Research & Innovation
    • Data & Infographics
    • Special Reports/Features
    • Investigations
    • Interviews
    • Markets
  • Arts/Life
    • Arts/Books
    • Kannywood
    • Lifestyle
    • Music
    • Nollywood
    • Travel
  • Sports
    • Football
    • More Sports News
    • Sports Features
  • Projects
    • #EndSARS Dashboard
    • Parliament Watch
    • Panama Papers
    • Paradise Papers
    • AGAHRIN
Premium Times Nigeria
BUA Group Ad BUA Group Ad BUA Group Ad
ADVERTISEMENT
New research holds promise of a shorter treatment course for people with drugresistant- TB. Daniel Irungu/EPA

New research holds promise of a shorter treatment course for people with drugresistant- TB. [Photo: The Conversation - Daniel Irungu/EPA]

Drug-resistant TB: a new study offers new hope

byThe Conversation
March 22, 2019
3 min read

By Andrew Nunn, UCL and I.D. Rusen, University of Toronto

Tuberculosis (TB) is the leading cause of death in the world from a single infectious disease, causing more deaths than HIV/AIDS. In 2017, 10 million people developed TB disease globally and an estimated 1.6 million died.

One of the biggest blocks to beating the epidemic is the growing resistance to drugs that have previously cured TB.

The World Health Organisation (WHO) has declared drug-resistant TB a global health crisis. Worldwide in 2017, an estimated 558,000 people developed TB that was resistant to the most effective first-line drug – rifampicin (RR-TB). Of these, 82% had multidrug-resistant TB.

But treating drug-resistant TB is still hopelessly inefficient. The 20-month to 24-month regimen used in many countries to treat people is costly and has significant side effects. In addition, the length of the regimen makes it hard for patients to adhere to, as well as for health systems to sustain. Globally, the regimen has an average treatment success rate of little more than 50% in real-world treatment settings, although there is considerable variation from country to country.

As a result researchers around the world have been urgently exploring shorter, more effective, and safer treatments for patients who have drug-resistant TB.

One of these efforts has begun to bear fruit. Results from Stage 1 of a clinical trial have recently been published. The news is encouraging. The trial provides evidence that a shorter treatment regimen – of nine to 11 months – is as effective for the treatment of multidrug-resistant TB as the longer, 20-month treatment recommended by the WHO in 2011.

The STREAM trial presents robust evidence for the effectiveness and safety of the nine to 11-month regimen when compared to the much longer 20-month regimen. The results are as good and the fact that the regimen is shorter should make it much more acceptable to patients. It is also likely to result in cost saving to both patients and health services.

The trial

The STREAM trial (Standardised Treatment Regimen of Anti-TB Drugs for Patients with MDR-TB) is the world’s first multi-country randomised phase III clinical trial to test the efficacy, safety and economic impact of shortened MDR-TB treatment regimens. The randomised nature of the trial means that patients were assigned to the long or short regimen in such a way as so as to avoid bias. Treatment allocation is determined by chance not by the choice of a physician.

RelatedNews

It’s Fake: CAN, NSCIA say of document linking Pantami to Yakowa assassination plot

Nigeria businesses lose $29 billion annually to poor electricity

UPDATED : How Deby’s death in Chad may affect Nigeria’s security – FG

Reps to investigate export of over 7,000 ‘refrigerated penis’ to China

Phase III trials are designed to assess the effectiveness and safety of a new intervention in practice.

Stage 1 of the trial was designed to assess whether a nine to 11-month treatment regimen that demonstrated promising cure rates during a pilot programme in Bangladesh, is as effective as the longer regimen when assessed in other settings under rigorous control trial conditions. Seven sites in Vietnam, Mongolia, South Africa, and Ethiopia participated.

The results from Stage 1 show that the shorter regimen is as good as the 20-month regimen.

TEXEM

Nearly 80% of patients in the trial showed a favourable outcome after two and a half years of follow-up from entry into the trial. The percentage was 79.8% in the 20-month regimen. In the nine to 11-month regimen the percentage was 78.8%.

Results in participants with HIV, although not as good as in those who were HIV-negative, were very similar in the short and long regimen.

The findings on side-effects were also interesting. There were very similar rates of severe side-effects during treatment and follow-up between the two regimens. But there were differences in the types of side-effects. The most common side-effects were cardiac conduction disorders, which increase the risk of serious and potentially fatal arrhythmias, in the nine to 11-month regimen. In the 20-month regimen the most common side effects were metabolic disorders, particularly hypokalemia.

A health economics data analysis is ongoing and will assess potential cost savings to patients and health systems when the nine to 11-month regimen is compared to the 20-month regimen.

Conclusions

The final results from the trial are encouraging because they show that the nine to 11-month treatment regimen is comparable in efficacy and safety to the 20-month regimen. This supports the use of a shorter regimen for patients with rifampicin-resistant TB.

The nine to 11-month regimen presents substantial advantages. It reduces treatment times, may improve patient retention under programmatic conditions, and reduces the number of pills patients have to take.

ADVERTISEMENT

However, the required ECG monitoring is an important consideration.

In its latest guidelines issued last year the WHO again highlighted the need to continue to look for regimens that are not only shorter, but are also less toxic for the patient. The STREAM Stage 1 results suggest that some progress is being made.

STREAM Stage 2 is currently evaluating an all-oral regimen that is potentially as effective and more tolerable than the injectable-containing regimens currently used some countries. This, too, would be another major step forward in the battle against MDR-TB.

Andrew Nunn, Senior scientist, MRC Clinical Trials Unit at UCL, UCL and I.D. Rusen, Adjunct Professor, Dalla Lana School of Public Health , University of Toronto

This article is republished from The Conversation under a Creative Commons license. Read the original article.

The conversation
The conversation
  • WhatsApp
  • Tweet
  • Email
  • Print
  • Telegram
  • More
  • Share on Tumblr
  • Pocket

Support PREMIUM TIMES' journalism of integrity and credibility

Good journalism costs a lot of money. Yet only good journalism can ensure the possibility of a good society, an accountable democracy, and a transparent government.

For continued free access to the best investigative journalism in the country we ask you to consider making a modest support to this noble endeavour.

By contributing to PREMIUM TIMES, you are helping to sustain a journalism of relevance and ensuring it remains free and available to all.

Donate


TEXT AD: To advertise here . Call Willie +2347088095401...


JOIN THE CONVERSATION

  • Disqus (0)
premiumtimes



PT Mag Campaign AD

Previous Post

#SheVentures – 4 Reasons Every Nigerian Business Woman Should Seriously Consider This New Proposition

Next Post

NUJ reacts to CCT Chairman Danladi Umar’s threat against journalists

The Conversation

The Conversation

More News

Nigerian map showing oil producing states (PHOTO CREDIT: Researchgate)

ANALYSIS: How state governments cheat oil-producing communities in use of 13% derivation fund

April 23, 2021
polio vaccination exercise

COVID-19: 16.6 million Africa children miss measles vaccination – WHO

April 23, 2021
Lagos State Governor, Babajide Sanwo-Olu [PHOTO CREDIT: @jidesanwoolu]

Lagos JUSUN backtracks on partial suspension of strike

April 23, 2021
Lagos State Isolation centre Onikan [PHOTO CREDIT: The Africa Report.com]

COVID-19: Nigeria records zero deaths in 10 days, 100 new cases

April 23, 2021
Vaccination-of-Gov.-Ifeanyi-Ugwuanyi

COVID-19: Nigeria vaccinates additional 14,843 people

April 23, 2021
Vice President Yemi Osinbajo

NEC backs finance minister, says no money printed

April 22, 2021
Next Post
Danladi Umar, the Chairman of the tribunal

NUJ reacts to CCT Chairman Danladi Umar's threat against journalists

President Muhammadu Buhari at the APC Caucus meeting today

Buhari inaugurates panel for state legislature, judiciary autonomy

Discussion about this post

Search

#EndSARS: Latest Updates




Polaris Bank


JAIZ Ad


Explore Akwa Ibom Ad


Explore Akwa Ibom Ad


Access Bank Ad


NITDA Ad





Glo Ad

Subscribe to News via Email

Enter your email address and receive notifications of news by email.

Join 1,656,180 other subscribers.

Advertisement






netherland biz school Advert



Zenith Advert

ADVERTISEMENT

Our Digital Network

  • PT Hausa
  • Election Centre
  • Human Trafficking Investigation
  • Centre for Investigative Journalism
  • National Conference
  • Press Attack Tracker
  • PT Academy
  • Dubawa
  • LeaksNG
  • Campus Reporter

Resources

  • Oil & Gas Facts
  • List of Universities in Nigeria
  • LIST: Federal Unity Colleges in Nigeria
  • NYSC Orientation Camps in Nigeria
  • Nigeria’s Federal/States’ Budgets since 2005
  • Malabu Scandal Thread
  • World Cup 2018
  • Panama Papers Game
  • Our Digital Network
  • About Us
  • Resources
  • Projects
  • Data & Infographics
  • DONATE

All content is Copyrighted © 2020 The Premium Times, Nigeria

No Result
View All Result
  • Home
  • COVID-19
  • News
    • Headline Stories
    • Top News
    • More News
    • Foreign
  • Investigations
  • Business
    • News Reports
    • Financial Inclusion
    • Analysis and Data
    • Business Specials
    • Opinion
    • Oil/Gas Reports
      • FAAC Reports
      • Revenue
  • Agriculture
    • News Report
    • Research & Innovation
    • Data & Infographics
    • Special Reports/Features
    • Investigations
    • Interviews
    • Markets
  • Arts/Life
    • Arts/Books
    • Kannywood
    • Lifestyle
    • Music
    • Nollywood
    • Travel
  • Sports
    • Football
    • More Sports News
    • Sports Features
  • Projects
    • Panama Papers
    • Paradise Papers
    • Parliament Watch
    • AGAHRIN
  • Opinion
  • PT Hausa
  • The Membership Club
  • Dubawa
    • Dubawa NG
  • About Us
    • Advert Rates
  • Careers
  • Contact Us
  • Digital Store
  • DONATE

All content is Copyrighted © 2020 The Premium Times, Nigeria

Our website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.